HLA-A*26  	HLA-A*26  	 NNP	B-NP
and  	and  	 CC	O
susceptility  	susceptility  	 NN	B-NP
of  	of  	 IN	O
iranian  	iranian  	 JJ	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
non-Hodgkin  	non-Hodgkin  	 JJ	B-NP
lymphoma  	lymphoma  	 JJ	I-NP
Non-Hodgkin  	Non-Hodgkin  	 JJ	I-NP
lymphoma  	lymphoma  	 NNS	I-NP
( 	( 	 -LRB-	O
NHL 	NHL 	 NNP	B-NP
)  	)  	 -RRB-	O
includes  	includes  	 VBZ	O
a  	a  	 DT	O
wide  	wide  	 JJ	O
range  	range  	 NN	O
of  	of  	 IN	O
diseases  	diseases  	 NNS	O
with  	with  	 IN	O
different  	different  	 JJ	O
clinical  	clinical  	 JJ	O
and  	and  	 CC	O
biological  	biological  	 JJ	B-NP
features 	features 	 NNS	I-NP
.  	.  	 .	O
NHL  	NHL  	 NNP	B-NP
is  	is  	 VBZ	O
usually  	usually  	 RB	O
presented  	presented  	 VBN	O
as  	as  	 IN	O
localized  	localized  	 NN	O
or  	or  	 CC	O
generalized  	generalized  	 JJ	O
lymphadenopathy 	lymphadenopathy 	 NN	B-NP
.  	.  	 .	O
It  	It  	 PRP	O
has  	has  	 VBZ	O
been  	been  	 VBN	O
suggested  	suggested  	 VBN	O
that  	that  	 IN	O
the  	the  	 DT	O
HLA  	HLA  	 NNP	B-NP
class  	class  	 NN	I-NP
I  	I  	 PRP	I-NP
and  	and  	 CC	O
II  	II  	 NNP	O
are  	are  	 VBP	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
susceptibility  	susceptibility  	 VBG	O
to  	to  	 TO	O
NHL 	NHL 	 NNP	B-NP
.  	.  	 .	O
Different  	Different  	 JJ	B-NP
ethnic  	ethnic  	 JJ	I-NP
groups  	groups  	 NNS	I-NP
have  	have  	 VBP	O
been  	been  	 VBN	O
found  	found  	 VBN	O
to  	to  	 TO	O
have  	have  	 VB	O
different  	different  	 JJ	O
HLA  	HLA  	 NNP	B-NP
class  	class  	 NN	I-NP
I  	I  	 PRP	I-NP
and  	and  	 CC	O
II  	II  	 NNP	O
alleles  	alleles  	 NN	B-NP
which  	which  	 WDT	O
affect  	affect  	 VBP	O
NHL 	NHL 	 NNP	B-NP
.  	.  	 .	O
To  	To  	 TO	O
evaluate  	evaluate  	 VB	O
the  	the  	 DT	O
association  	association  	 NN	O
of  	of  	 IN	O
HLA  	HLA  	 NNP	B-NP
class  	class  	 NN	I-NP
I  	I  	 PRP	I-NP
and  	and  	 CC	O
class  	class  	 NN	O
II  	II  	 NNP	O
with  	with  	 IN	O
Non-Hodgkin 	Non-Hodgkin 	 NNP	O
's  	's  	 POS	O
lymphoma  	lymphoma  	 NN	B-NP
in  	in  	 IN	O
Iranian  	Iranian  	 JJ	O
patients 	patients 	 NNS	O
.  	.  	 .	O
We  	We  	 PRP	O
performed  	performed  	 VBD	O
a  	a  	 DT	O
case-control  	case-control  	 JJ	B-NP
genotyping  	genotyping  	 JJ	I-NP
study  	study  	 NN	I-NP
on  	on  	 IN	O
75  	75  	 CD	O
Iranian  	Iranian  	 JJ	O
NHL  	NHL  	 NN	B-NP
patients  	patients  	 NNS	I-NP
who  	who  	 WP	O
were  	were  	 VBD	O
selected  	selected  	 VBN	O
from  	from  	 IN	O
among  	among  	 IN	O
the  	the  	 DT	O
patients  	patients  	 NNS	O
referred  	referred  	 VBD	O
to  	to  	 TO	O
the  	the  	 DT	O
Bone  	Bone  	 NNP	O
Marrow  	Marrow  	 NNP	O
Transplantation  	Transplantation  	 NNP	O
Department  	Department  	 NNP	O
of  	of  	 IN	O
Taleghani  	Taleghani  	 NNP	O
Hospital  	Hospital  	 NNP	O
and  	and  	 CC	O
120  	120  	 CD	O
apparently  	apparently  	 RB	O
healthy  	healthy  	 JJ	O
control  	control  	 NN	B-NP
subjects  	subjects  	 NNS	I-NP
using  	using  	 VBG	O
the  	the  	 DT	O
SSP-PCR  	SSP-PCR  	 JJ	B-NP
by  	by  	 IN	O
a  	a  	 DT	O
commercial  	commercial  	 JJ	B-NP
kit 	kit 	 NN	I-NP
.  	.  	 .	O
Our  	Our  	 PRP$	O
results  	results  	 NNS	O
demonstrated  	demonstrated  	 VBN	O
that  	that  	 IN	O
the  	the  	 DT	O
HLA-A*26  	HLA-A*26  	 NNP	B-NP
( 	( 	 -LRB-	O
p 	p 	 NN	O
:  	:  	 :	O
0.026 	0.026 	 CD	O
;  	;  	 :	O
OR 	OR 	 NNP	O
:  	:  	 :	O
8.5 	8.5 	 CD	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
HLA-B*35  	HLA-B*35  	 NNP	B-NP
( 	( 	 -LRB-	O
p 	p 	 NN	O
:  	:  	 :	O
0.022 	0.022 	 CD	O
;  	;  	 :	O
OR 	OR 	 NNP	O
:  	:  	 :	O
0.375 	0.375 	 CD	O
)  	)  	 -RRB-	O
alleles  	alleles  	 NN	B-NP
had  	had  	 VBD	O
positive  	positive  	 JJ	O
and  	and  	 CC	O
negative  	negative  	 JJ	B-NP
associations  	associations  	 NNS	I-NP
with  	with  	 IN	O
NHL  	NHL  	 NNP	B-NP
disease 	disease 	 NN	I-NP
,  	,  	 ,	O
respectively 	respectively 	 RB	O
.  	.  	 .	O
HLA-DRB1*13  	HLA-DRB1*13  	 NNP	B-NP
allele  	allele  	 NN	O
showed  	showed  	 VBD	B-NP
decrease  	decrease  	 NN	I-NP
of  	of  	 IN	O
frequency  	frequency  	 NN	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
in  	in  	 IN	O
comparison  	comparison  	 NN	O
with  	with  	 IN	O
the  	the  	 DT	O
controls 	controls 	 NNS	O
,  	,  	 ,	O
but  	but  	 CC	O
it  	it  	 PRP	O
did  	did  	 VBD	O
not  	not  	 RB	O
remain  	remain  	 VB	O
significant  	significant  	 JJ	O
after  	after  	 IN	O
correction 	correction 	 NN	O
.  	.  	 .	O
Our  	Our  	 PRP$	O
results  	results  	 NNS	O
conclude  	conclude  	 VBP	O
that  	that  	 IN	O
HLA-A*26  	HLA-A*26  	 NNP	B-NP
may  	may  	 MD	O
represent  	represent  	 VB	O
as  	as  	 IN	O
a  	a  	 DT	O
genetic  	genetic  	 JJ	B-NP
susceptibility  	susceptibility  	 JJ	I-NP
factors  	factors  	 NNS	I-NP
in  	in  	 IN	O
Iranian  	Iranian  	 JJ	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
Non-Hodgkin 	Non-Hodgkin 	 NNP	O
's  	's  	 POS	O
lymphoma 	lymphoma 	 NN	B-NP
,  	,  	 ,	O
a  	a  	 DT	O
finding  	finding  	 NN	O
which  	which  	 WDT	O
generally  	generally  	 RB	O
supports  	supports  	 VBZ	O
contribution  	contribution  	 NN	B-NP
of  	of  	 IN	I-NP
genetic  	genetic  	 JJ	I-NP
factors  	factors  	 NNS	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
etiology  	etiology  	 NN	O
of  	of  	 IN	O
this  	this  	 DT	O
disorder 	disorder 	 NN	O
.  	.  	 .	O
In  	In  	 IN	O
addition 	addition 	 NN	B-NP
,  	,  	 ,	O
these  	these  	 DT	O
results  	results  	 NNS	O
may  	may  	 MD	O
be  	be  	 VB	O
useful  	useful  	 JJ	O
in  	in  	 IN	O
designing  	designing  	 VBG	O
a  	a  	 DT	O
peptide  	peptide  	 NN	B-NP
based  	based  	 VBN	O
vaccine  	vaccine  	 NN	O
for  	for  	 IN	O
the  	the  	 DT	O
Iranian  	Iranian  	 JJ	O
NHL  	NHL  	 NN	B-NP
patients  	patients  	 NNS	I-NP
with  	with  	 IN	O
HLA-A*26 	HLA-A*26 	 CD	B-NP
.  	.  	 .	O
